Replies to post #378472 on Amarin Corp Plc (AMRN)

[Pharmacydude]

Dogn
Was there ever any clarity given on why the approval in China was delayed a year?

[HDGabor]

d-

Good summary.

Best,
G

[Whalatane]

We’ll consider me skeptical.
For example his comments on “injectable’s “ as if PCSK9 is interchangeable with Vascepa

Injectable’s … ie Repatha is for dramatically cutting LDL cholesterol levels

No one is telling an HeFH patient with LDL between 200-500 mg / dl to be taking Vascepa instead .

So there’s a lot of that in his pitch … Oh we can extend EU exclusivity by X number of years by running a combo trial with another lipid lowering drug .

Big deal … way off in the future

I want to know what are U doing now to control costs and avoid another Q1 earnings disaster … before U gain traction in the EU

Kiwi

[lizzy241]

dogn, after further researching the Edding situation the last IPO filing was in 2020. Maybe that's why KM mentioned they are in talks with a few BP to partner with outside of the EU. Maybe they have written off Edding as a partner?? I hope that's accurate, amarin may have to give up a few shekels but will be worth it in order to effectively market V.
Plus the lockdown in China isn't helping the situation.